跳转至内容
Merck
CN

M-106

霉酚酸标准液 CRM 溶液

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C17H20O6
化学文摘社编号:
24280-93-1
分子量:
320.34
NACRES:
NA.24
UNSPSC Code:
41116107

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

霉酚酸标准液 CRM 溶液, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

InChI

1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+

InChI key

HPNSFSBZBAHARI-RUDMXATFSA-N

SMILES string

COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in acetonitrile

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−70°C

Quality Level

300

Gene Information

human ... IMPDH1(3614), IMPDH2(3615)

相关类别

General description

在治疗药物监测中进行分析，以确保患者保持在药物治疗范围内，霉酚酸是一种免疫抑制药物，也是前药霉酚酸酯的活性代谢物。本分析标准适用于 LC-MS/MS 应用，包括治疗药物监测和其他临床或诊断应用。

Preparation Note

本品含有 1 mL 安瓿，浓度为 1.0 mg/mL 的乙腈溶液。

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

pictograms

FlameExclamation mark
GHS02,GHS07

signalword

Danger

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - Eye Irrit. 2 - Flam. Liq. 2

存储类别

3 - Flammable liquids

wgk

WGK 2

flash_point_f

35.6 °F - closed cup

flash_point_c

2 °C - closed cup

法规信息

危险化学品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

David Wofsy et al.
Arthritis and rheumatism, 65(6), 1586-1591 (2013-03-27)
Clinical trials of therapies for lupus nephritis have used many different primary outcome measures, ranging from complete response to time to end-stage renal disease. The objective of this study was to compare several possible outcome measures, using data from a
Mycophenolate mofetil in severe lupus nephritis: should post hoc analyses change treatment patterns?
Jonathan J Hogan et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 61(5), 692-693 (2013-04-16)
CD25 blockade for refractory polymyositis.
Nicolò Pipitone et al.
Clinical and experimental rheumatology, 31(3), 474-474 (2013-03-08)
Nathan R Selden et al.
Journal of neurosurgery. Pediatrics, 11(6), 643-652 (2013-04-16)
Infantile and late-infantile neuronal ceroid lipofuscinoses (NCLs) are invariably fatal lysosomal storage diseases associated with defects in lysosomal enzyme palmitoyl-protein thioesterase 1 (PPT-1) or tripeptidyl peptidase 1 (TPP1) activity. Previous preclinical studies have demonstrated that human CNS stem cells (HuCNS-SCs)
Hui Chen et al.
Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology, 27(1), 35-38 (2013-07-17)
It is well known that cyclosporine A (CsA), a widely used immunosuppressant for clinical organ transplantation, has the ability to inhibit HCV replication. In this study, the effects of several other immunosuppressants, including mycophenolic acid (MPA), rapamycin and FK-506, on
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持